Pear Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	Current	2022	2021	2020	2019
Market Capitalization	0	165	854	-	-
Market Cap Growth	-	-80.73%	-	-	-
Enterprise Value	-20	144	707	-99	-91
PE Ratio	-2.18	-2.18	-13.11	-	-
PS Ratio	0.00	12.97	203.03	-	-
PB Ratio	5.38	5.38	9.45	-	-
P/FCF Ratio	-1.40	-1.40	-7.61	-	-
P/OCF Ratio	-1.45	-1.45	-7.84	-	-
EV/Sales Ratio	11.36	11.36	168.12	-10.50	-2.80
EV/EBITDA Ratio	-2.19	-2.19	-12.04	1.04	8.65
EV/EBIT Ratio	-2.01	-2.01	-11.60	1.03	8.48
EV/FCF Ratio	-1.23	-1.23	-6.30	1.37	2.47
Debt / Equity Ratio	1.27	1.27	0.31	0.31	-0.23
Debt / EBITDA Ratio	-0.59	-0.59	-0.47	-0.28	-1.44
Debt / FCF Ratio	-0.33	-0.33	-0.25	-0.38	-0.41
Quick Ratio	1.34	1.34	3.74	3.09	6.28
Current Ratio	1.48	1.48	3.93	3.10	6.26
Asset Turnover	0.10	0.10	0.03	0.08	-
Interest Coverage	-18.40	-18.40	-14.72	-53.91	-
Return on Equity (ROE)	-130.50%	-130.50%	-73.40%	-1025.70%	-
Return on Assets (ROA)	-57.00%	-57.00%	-39.50%	-89.30%	-
Return on Capital (ROIC)	-177.64%	-177.64%	-89.49%	-67.15%	62.11%
Earnings Yield	-53162676.06%	-45.85%	-7.62%	-	-
FCF Yield	-82651408.45%	-71.28%	-13.15%	-	-
Buyback Yield / Dilution	-22.39%	-22.39%	-27.03%	-504.42%	-
Total Shareholder Return	-22.39%	-22.39%	-27.03%	-504.42%	-

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).